Oncology Institute Of Southern Switzerland

This study was designed to explore how the drug ruxolitinib affects immune cells inside prostate tumors. Researchers planned to give the drug to men with prostate cancer for 28 days before their scheduled surgery, then analyze tumor and blood samples. However, the study was withd…

This study aims to create a more accurate tool to predict whether follicular lymphoma patients will remain free of disease progression two years after their first treatment. Researchers will combine clinical information with molecular data from 370 patients to build and test this…